Preliminary consolidated sales results of JSC Olainfarm for January 2014, show that sales have reached 9.67 million euros, which is an increase by 24% compared to the same period one year ago. The biggest sales increases have been achieved in Georgia, where sales grew by 3496%, Spain, where sales grew by 843%, Italy, where sales grew by 321%, Lithuania, where sales grew by 126% and Latvia, where sales grew by 101%. Major sales markets of JSC Olainfarm in January 2014 were Russia, Latvia, Ukraine, Belarus, The UK and The Netherlands. During January 2014 almost half a million euros worth of sales have also been made to The Netherlands.
|January 2014, consolidated results||Share in total sales||Changes to January 2013|
Sales of pharmacy chain of LTD Latvijas aptieka owned by JSC Olainfarm in January were 1.4 million euros. There were 54 pharmacies operating in January. Sales of LTD Silvanols in January were 0.29 million euros.
According to preliminary unconsolidated results of JSC Olainfarm sales made in January were worth 8.43 million euros, which is an increase by 20% compared to the same period one year ago. The biggest sales increases were achieved in Georgia, where sales grew by 3496%, Azerbaijan, where sales grew by 883%, Spain, where sales grew by 843% and Italy, where sales grew by 321%. Major sales markets of JSC Olainfarm during January 2014 were Russia, Ukraine, Belarus, Latvia, UK and The Netherlands. In total sales to 19 countries in 2 continents have been made during January.
|January 2014 unconsolidated results||Share in total sales||Changes to January 2013|
According to preliminary targets, unconsolidated sales of Olainfarm in 2014 are planned at 80 million euros, while consolidated sales are planned at 90 million euros. According to these preliminary sales figures, during January 2014, 11% of annual sales target for unconsolidated sales and 11% of annual target for consolidated sales are achieved.
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Member of the Board
Tel: +371 6 7013 717
Cell: +371 2 6448 873